Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1997;96:2171-2177

This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tomai, F.
Right arrow Articles by Gioffrè, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tomai, F.
Right arrow Articles by Gioffrè, P. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Angioplasty
Hazardous Substances DB
*PHENTOLAMINE

(Circulation. 1997;96:2171-2177.)
© 1997 American Heart Association, Inc.


Articles

Phentolamine Prevents Adaptation to Ischemia During Coronary Angioplasty

Role of {alpha}-Adrenergic Receptors in Ischemic Preconditioning

Fabrizio Tomai, MD; Filippo Crea, MD; Achille Gaspardone, MD, MPhil; Francesco Versaci, MD; Anna S. Ghini, MD; Ruggero De Paulis, MD; Luigi Chiariello, MD; ; Pier A. Gioffrè, MD

From the Servizio Speciale di Diagnosi e Cura di Emodinamica (F.T., A.G., F.V., A.S.G., R.De P., L.C., P.A.G.), Divisione di Cardiochirurgia, Università di Roma Tor Vergata, European Hospital; and Istituto di Cardiologia (F.C.), Università Cattolica del Sacro Cuore, Rome, Italy.

Correspondence to Dr Fabrizio Tomai, Divisione di Cardiochirurgia, Università di Roma Tor Vergata, European Hospital, via Portuense 700, 00149 Rome, Italy.


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background Experimental studies indicate that {alpha}-adrenergic receptors are involved in ischemic preconditioning. Their role in humans is unknown.

Methods and Results Eighteen patients undergoing angioplasty for an isolated stenosis of the left anterior descending coronary artery were randomized to receive intravenous infusion of phentolamine or placebo during the procedure. Intracoronary ECG and cardiac pain were determined at the end of the first two balloon inflations. Average peak velocity in the contralateral coronary artery during balloon occlusion, an index of collateral recruitment, was also assessed by using a Doppler guide wire. In both phentolamine- and placebo-treated patients, average peak velocity significantly increased from baseline to the end of the first inflation (P<.01), but it did not show any further increase during the second inflation. In phentolamine-treated patients, ST-segment changes and cardiac pain severity during the second inflation were similar to those observed during the first inflation (13±9 versus 12±8 mm, P=NS, and 51±34 versus 54±32 mm, P=NS, respectively), whereas in placebo-treated patients, they were significantly less (6±4 versus 13±7 mm, P<.01, and 26±20 versus 49±22 mm, P<.05, respectively).

Conclusions The adaptation to ischemia observed in humans after two sequential coronary balloon inflations is abolished by phentolamine and is independent of collateral recruitment. Thus, it occurs due to ischemic preconditioning and is, at least in part, mediated by {alpha}-adrenergic receptors.


Key Words: angioplasty • receptors, adrenergic, alpha • collateral circulation


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Ischemic preconditioning, a powerful form of myocardial protection from irreversible ischemic injury, has been shown in all animal species investigated1 2 3 4 and, recently, in isolated human myocytes5 and atrial trabeculae.6 There is evidence indicating that ischemic preconditioning also occurs in humans in the setting of coronary angioplasty7 8 and coronary artery bypass graft surgery.9

It has recently been demonstrated that the ischemic preconditioning observed during coronary angioplasty after repeated balloon inflations is abolished by pretreatment with glibenclamide,10 theophylline,11 and bamifylline,12 suggesting that the activation of both ATP-sensitive K+ (KATP) channels and A1 adenosine receptors plays a role in this phenomenon. Several experimental studies have shown, however, that preconditioning results from a complex series of events, involving a variety of G protein-coupled receptors.13 14 In particular, recent studies have shown that activation of {alpha}1-adrenergic receptors mimics and their blockade abolishes ischemic preconditioning.15 16 17 Moreover, in cardiomyocytes, {alpha}1-adrenergic receptors couple with protein kinase C (PKC),18 19 20 21 which seems to play a pivotal role in preconditioning in several animal species13 14 17 22 23 24 and in human atrial trabeculae.25

To establish the role played by {alpha}-adrenergic receptors in preconditioning in humans, we assessed the effect of phentolamine, a nonselective {alpha}-adrenergic receptor antagonist,26 in patients undergoing repeated coronary occlusions in the setting of elective angioplasty of an isolated stenosis on the left anterior descending coronary artery. Because collateral recruitment can occur during coronary angioplasty27 28 29 and can be affected by phentolamine,30 31 32 changes in blood flow velocity in the contralateral coronary artery during balloon occlusions, an accepted index of collateral recruitment,33 34 35 were also measured by using an intracoronary Doppler guide wire.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Patients
We studied 18 consecutive patients (16 men and 2 women; age, 43 to 77 years; mean age, 55 years) who underwent successful uncomplicated elective coronary angioplasty for an isolated obstructive lesion (internal diameter reduction comprised 50% to 90% on the basis of the use of the quantitative cardiovascular software program ACA, Philips, DCI)36 in the proximal two thirds of the left anterior descending coronary artery. Patients with stenoses of >90% were not included in the study to avoid "preinflation ischemia" due to obstruction from the guide wire across the lesion, which would prolong the ischemic time of the first inflation compared with the second.37 All patients fulfill the entry criteria of (1) history of chronic stable angina pectoris lasting >=3 months, (2) no history of previous myocardial infarction, (3) no angiographic evidence of coronary collateral vessels (grade 0, according to Rentrop's classification),27 and (4) right dominant coronary circulation. No patient had evidence of left ventricular hypertrophy on the echocardiogram or conduction defects on the ECG that could have interfered with the interpretation of ST-segment changes. All patients had normal hepatic and renal function and fasting blood glucose levels. All patients gave written informed consent for participation in the study, which was approved by the Institutional Ethics Committee.

Study Protocol
In this single-blind study, which was performed within 5 days of the diagnostic coronary angiography, patients were randomly allocated to one of two groups. One group consisted of nine patients (eight men and one woman; age range, 47 to 77 years; mean age, 58 years) who received an intravenous infusion of phentolamine (phentolamine mesylate 50 mg/5 mL dissolved in 50 mL 0.9% NaCl; Ciba-Geigy SA). The infusion was started 15 minutes before coronary angioplasty and was stopped at the end of the second inflation. The infusion rate of phentolamine was titrated individually according to the hemodynamic response observed; the drug was considered to be effective when a stable drop of >=10 mm Hg in systolic arterial pressure or an increase of 10 bpm in heart rate was observed. Doses ranged from 0.4 to 0.7 mg/min. The other group consisted of nine patients (eight men and one woman; age range, 43 to 60 years, mean age, 53 years) who received an intravenous infusion of placebo (0.9% NaCl) started 15 minutes before coronary angioplasty and stopped at the end of the second inflation. ß-Blocking agents were withdrawn 5 days before the study. All patients were receiving oral aspirin (100 mg OD), diltiazem (60 mg TID), and isosorbide dinitrate (40 mg BID) for >=48 hours before coronary angioplasty. All patients received the morning dose of treatment before coronary angioplasty, which was performed within the next 4 hours. No patient received sublingual or intravenous nitrates in the last 24 hours before the study or throughout the study. Patients were not premedicated with diazepam or other sedatives.

An 8F and a 5F femoral sheath were inserted in the right and left femoral arteries, respectively. A 5F right Judkins femoral catheter was advanced through the left femoral sheath into the ostium of the right coronary artery for guidance of a 0.014-in Doppler-tipped guide wire (FloWire, Cardiometrics, Inc). Coronary angioplasty of the stenosed artery was performed by a standard technique using the right femoral approach, as previously described.10 Briefly, after placement of the guiding catheter through the right femoral sheath and performance of baseline angiography, the guide wire was placed across the lesion in the distal segment of the stenosed artery. The balloon catheter was then placed within the stenosis, and the balloon was inflated for 2 minutes. After balloon deflation and withdrawal proximal to the lesion, with the guide wire still across the lesion, a recovery period of >=5 minutes was allowed to reestablish baseline hemodynamic and ECG conditions. A second balloon inflation for 2 minutes was then performed. In each individual patient, balloon pressure during the first and second inflations was identical. After the first two inflations, coronary angioplasty was completed on the basis of the specific needs of individual patients.

Assessment of Myocardial Ischemia
Standard surface 12-lead and intracoronary ECGs derived from the angioplasty guide wire were continuously monitored and simultaneously recorded (Mingograf 7, Siemens) at a paper speed of 25 mm/s throughout the study. The ECGs were analyzed by a cardiologist who had no knowledge of the study protocol. At baseline (with just the guide wire across the lesion) and at the end of the first two inflations, ST-segment shift was measured 80 milliseconds after the J point. The severity of myocardial ischemia was expressed as (1) the summation of the absolute values of the ST-segment elevation or ST-segment depression from baseline, on surface ECG, from all 12 leads; and (2) the absolute values of the ST-segment elevation or ST-segment depression from baseline on intracoronary ECG. ST-segment shifts were expressed in millimeters (1 mm=0.1 mV).

Assessment of Cardiac Pain
At the beginning of each coronary angioplasty procedure, patients were informed that they might develop chest pain. At the end of the first two balloon inflations, the intensity of cardiac pain was assessed by using a visual-analog scale.38 Patients were asked to put a mark on a 100-mm scale marked from no symptoms (0) to severe symptoms (100).

Assessment of Coronary Blood Flow Velocity
After heparinization (10 000 U IV) and placement of the angioplasty guiding catheter into the ostium of the left main coronary artery and before administration of phentolamine or placebo infusion, a 0.014-in Doppler-tipped intracoronary guide wire (FloWire and FloMap, Cardiometrics, Inc) was advanced through the 5F right Judkins catheter into the medium tract of the right coronary artery and positioned until an optimal and stable Doppler signal, not in the proximity of a side branch, was obtained. Blood flow velocity was calculated from the Doppler frequency shift of a reflected 15-MHz signal by fast Fourier transformation and displayed in a spectral format, as previously described.39 40 Flow velocity signals were continuously displayed throughout the study. Average peak velocity (cm/s) was derived automatically by the integrated signal-analyzing computer. Satisfactory velocity data were obtained for all 18 patients.

Average peak velocity in the contralateral artery was measured at baseline, before the first (15 minutes after phentolamine or placebo infusion) and the second balloon inflations and at the end of the first two inflations. Collateral recruitment was expressed as the changes in average peak velocity in the contralateral coronary artery during the first and second balloon inflations.

Statistical Analysis
Two-factor repeated-measures ANOVA with repeated measures on one factor was used to compare ischemic ECG and average peak velocity changes during balloon inflations in the two groups of patients. When significant differences were detected, pairwise comparisons were made using the Scheffé F test. Comparisons of the remaining continuous or discrete variables between the two groups were performed using an unpaired Student's t or a {chi}2 test, respectively. Visual-analog scales were analyzed using the Wilcoxon signed rank test or the Mann-Whitney U test as appropriate. Correlations between changes in average peak velocity from the first to the second inflation and changes in ST-segment shift or pain severity were assessed by univariate linear regression analysis. Data are expressed as mean±1 SD; values of P<.05 were considered significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
Clinical, anatomic, and hemodynamic features in the two groups of patients are summarized in Table 1Down. According to the study protocol, systolic arterial pressure significantly decreased (from 140±15 to 123±13 mm Hg, P<.05) and heart rate increased (from 76±6 to 82±6 bpm, P<.05) after the intravenous infusion of phentolamine but did not show any further change at the end of the first and the second inflations. Conversely, no significant changes in systolic arterial pressure or heart rate were detected after intravenous infusion of placebo. As a result, there was no significant difference between the two groups of patients in the rate-pressure product at baseline, 15 minutes after phentolamine or placebo infusion (immediately before the first balloon inflation), before the second balloon inflation, and at the end of the first two inflations (Table 1Down).


View this table:
[in this window]
[in a new window]
 
Table 1. Clinical, Anatomic, and Hemodynamic Features in the Two Groups of Patients

Coronary Angioplasty
Coronary angioplasty was successfully performed in all 18 patients (residual stenosis <50%) (Table 1Up). The mean balloon pressure was similar in phentolamine- and placebo-treated patients (4.3±0.7 versus 4±1.2 atm, respectively; P=NS). The recovery period between the two balloon inflations was similar in phentolamine- and placebo-treated patients (6.9±1.9 versus 6.8±1.6 minutes, respectively; P=NS).

Coronary Blood Flow Velocity
The values of average peak velocity in the contralateral artery at baseline, before the first (15 minutes after phentolamine or placebo infusion) and the second balloon inflations, and at the end of the first two inflations are reported in Table 2Down.


View this table:
[in this window]
[in a new window]
 
Table 2. Values of ST-Segment Shift, Cardiac Pain Severity, and Average Peak Velocity in Contralateral Coronary Artery in the Two Groups of Patients

There was no significant difference between phentolamine- and placebo-treated patients in average peak velocity at baseline (23±4 versus 23±5 cm/s, respectively; P=NS), before the first balloon inflation (15 minutes after phentolamine or placebo infusion) (22±4 versus 23±5 cm/s, respectively; P=NS), and before the second balloon inflation (23±4 versus 23±3 cm/s, respectively; P=NS). Within each group, the values of average peak velocity at the three time points were also similar (P=NS) (Table 2Up).

In both phentolamine- and placebo-treated patients, average peak velocity in the right coronary artery significantly increased from baseline to the end of the first inflation (from 22±4 to 28±6 cm/s, P<.01, and from 23±5 to 28±6 cm/s, P<.01, respectively) but did not show a further increase during the second inflation (28±4 and 29±4 cm/s, respectively; P=NS versus the first inflation) (Fig 1Down). Of note, there was no significant difference between the two groups of patients in average peak velocity at the end of the first (P=NS) and the second inflation (P=NS) (Table 2Up). Average peak velocity increased by >20% at the end of the first inflation compared with baseline in five (55%) phentolamine-treated patients and five (55%) placebo-treated patients (P=NS). Similarly, average peak velocity increased by >20% at the end of the second inflation compared with baseline in five (55%) phentolamine-treated patients and six (67%) placebo-treated patients (P=NS). In contrast, a further increase in average peak velocity from the first to the second inflation by >10% was detected in two (22%) phentolamine-treated patients and two (22%) placebo-treated patients only (P=NS).



View larger version (20K):
[in this window]
[in a new window]
 
Figure 1. Values of average peak velocity in the right coronary artery at baseline and at the end of each inflation in the two groups of patients. In both phentolamine- and placebo-treated patients, average peak velocity significantly increased from baseline to the end of the first inflation, but it did not show a further increase during the second inflation. Thick lines and squares indicate mean values; BI, balloon inflation.

Myocardial Ischemia
The ST-segment shift values at the end of the first two inflations, as changes from baseline, are reported in Table 2Up. In phentolamine-treated patients, the mean ST-segment shift at the end of the second balloon inflation was similar to that at the end of the first inflation on both the surface ECG (16±10 versus 13±11 mm, P=NS) and the intracoronary ECG (13±9 versus 12±8 mm, P=NS). Conversely, in placebo-treated patients, the mean ST-segment shift at the end of the second balloon inflation was significantly less than that at the end of the first inflation on both the surface ECG (9±4 versus 13±4 mm, P<.01) and the intracoronary ECG (6±4 versus 13±7 mm, P<.01) (Fig 2Down). The drug-inflation interaction for ST-segment changes on the surface and intracoronary ECGs was highly significant (P=.0025 and P=.003, respectively). Of note, there was no significant difference between the two groups of patients in the degree of ST-segment shift at the end of the first inflation on either surface (P=NS) or intracoronary (P=NS) ECG (Table 2Up). Finally, in both phentolamine- and placebo-treated patients, changes in average peak velocity from the first to the second inflation did not correlate with those in ST-segment shift on surface (r=.176, P=NS, and r=.081, P=NS, respectively) or intracoronary (r=.054, P=NS, and r=.187, P=NS, respectively) ECG.



View larger version (38K):
[in this window]
[in a new window]
 
Figure 2. Values of ST-segment shifts on the intracoronary ECG (IC-ECG) and of cardiac pain severity at the end of the first and second balloon inflations in the two groups of patients. In phentolamine-treated patients, ST-segment changes and cardiac pain severity at the end of the second balloon inflation were similar to those at the end of the first inflation. Conversely, in placebo-treated patients, ST-segment changes and cardiac pain severity at the end of the second balloon inflation were significantly less than those at the end of the first inflation.

Cardiac Pain
In phentolamine-treated patients, the severity of cardiac pain at the end of the second inflation was similar to that at the end of the first inflation (51±34 versus 54±32 mm, P=NS). Conversely, in placebo-treated patients, the severity of cardiac pain at the end of the second inflation was less than that at the end of the first inflation (26±20 versus 49±22 mm, P<.05) (Fig 2Up). Of note, there was no significant difference between the two groups of patients in cardiac pain severity (P=NS) at the end of the first inflation (Table 2Up). Finally, in both phentolamine- and placebo-treated patients, changes in average peak velocity from the first to the second inflation did not correlate with those in cardiac pain severity (r=.135, P=NS, and r=.113, P=NS, respectively).


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
The results of this study show that the adaptation to ischemia during coronary angioplasty is prevented by pretreatment with phentolamine, a nonselective antagonist of {alpha}-adrenergic receptors, and is independent of progressive collateral recruitment. In fact, we found that in phentolamine-treated patients, the mean ST-segment shift and the severity of cardiac pain at the end of the second balloon inflation were similar to those at the end of the first inflation, whereas in placebo-treated patients, they were significantly less. Although blood flow velocity in the contralateral coronary artery showed a significant increase during the first inflation in both groups of patients, it did not show a further increase during the second inflation; furthermore, it was not affected by phentolamine. Taken together, these findings confirm that the adaptation to ischemia during repeated balloon inflations is due to ischemic preconditioning and indicate that {alpha}-adrenergic receptors play an important role in this phenomenon.

A limitation of this study is the use of a single-blind design. However, the selection of objective ECG end points and the analysis of the results blind to treatment should substantially overcome the drawbacks of the single-blind design. Another limitation is that we based the assessment of myocardial ischemia on the ECG changes that do not represent direct evidence of ischemia and on the anginal pain severity, which is rather subjective. However, the surface 12-lead and the intracoronary ECGs represent well-accepted methods for the evaluation of myocardial ischemia during coronary angioplasty.7 8 10 11 12 41 42 Moreover, Shattock et al,43 who measured ST-segment changes in open-chest pigs subjected to two cycles of 8-minute ischemia and 8-minute reperfusion followed by 60-minute ischemia and 2-hour reperfusion, found that ST-segment changes provide a reliable index of preconditioning during the first few minutes of coronary occlusion. Regarding the assessment of the anginal pain, the visual-analog scale is a well-accepted method for the evaluation of pain perception,38 which we used in several previous studies.8 10 12 44 45 Finally, with the number of patients being small, it may be argued that the failure of phentolamine to prevent the adaptation to ischemia during repeated balloon inflations could have been due to the power of the study, which was not very high: 83% at an {alpha} level of .05. However, ST-segment changes in phentolamine-treated patients were smaller than those observed in placebo-treated patients, with a highly significant drug-inflation interaction, thus indicating that phentolamine, compared with placebo, was able to prevent the reduction of ECG ischemic changes after repeated balloon inflations.

Mechanisms of Adaptation to Ischemia During Coronary Angioplasty
Because collateral recruitment can occur during coronary angioplasty,27 28 29 we assessed changes in blood flow velocity in the contralateral coronary artery during balloon occlusion by using a Doppler guide wire. In the absence of significant changes in arterial pressure or heart rate, as was the case in our study at the end of both inflations, blood flow velocity changes in the contralateral coronary artery have been shown to be a reliable index of collateral perfusion and function during coronary angioplasty and more accurate than thermodilution, measurement of coronary occlusion pressure through the balloon catheter, or angiographic visualization of collateral vessels.33 34 35 We found that coronary blood flow velocity significantly increased at the end of the first inflation in both groups of patients, whereas it exhibited a modest further increase during the second inflation in only {approx}20% of the patients and did not correlate with the changes in ST-segment shift or cardiac pain severity after two 2-minute balloon occlusions. Our findings are in agreement with those of Kyriakidis et al,35 who assessed collateral recruitment by using a Doppler flow velocimeter positioned in the proximal right coronary artery in patients undergoing four sequential 90-second balloon inflations for single left anterior descending coronary artery stenosis. They found that only {approx}30% of their patients exhibited progressive collateral recruitment after the first inflation. Cribier et al,46 who assessed collateral recruitment by using ipsilateral and contralateral injections of contrast medium and coronary wedge pressure in patients with isolated stenosis of the left anterior descending coronary artery undergoing five sequential balloon inflations, found an increase of collateral angiographic grade and coronary wedge pressure during the first coronary occlusion and a further increase during the fourth coronary inflation in one half of their patients. However, in our study, as in most angioplasty studies aimed at assessing ischemic preconditioning, only the first two (or three) inflations were taken into account.7 8 10 11 12 Thus, in our study, the adaptation to ischemia during coronary angioplasty was mainly determined by ischemic myocardial preconditioning.

Role of {alpha}-Adrenergic Receptors in Ischemic Preconditioning
Phentolamine is a nonselective antagonist of {alpha}-adrenergic receptors, which are present at presynaptic sympathetic nerve terminals, in endothelial cells, in smooth muscle cells, and in cardiomyocytes.31 47

The blockade by phentolamine of presynaptic {alpha}1- and {alpha}2-adrenergic receptors causes an increase in catecholamine release31 47 and might influence the severity of myocardial ischemia during balloon occlusion in two different ways. First, an increase in catecholamine release may increase myocardial oxygen consumption, thus worsening the severity of myocardial ischemia during coronary occlusion. However, if this were the case, we should have obtained greater ECG changes and more severe pain in phentolamine-treated patients also at the end of the first inflation. Instead, the magnitude of ischemic ECG changes, severity of pain, and systemic hemodynamic parameters at the end of the first inflation were similar in phentolamine- and placebo-treated patients. Second, an increase in catecholamine release may enhance preconditioning.15 16 17 However, if this were the case, presynaptic {alpha}-adrenergic receptor blockade by phentolamine should have resulted in cardioprotection rather than prevention of preconditioning. Thus, in agreement with experimental observations,15 16 17 it would appear that the blockade of presynaptic {alpha}-adrenergic receptors located on perivascular sympathetic nerves does not account for the results observed in our study.

The infusion of phentolamine did not affect blood flow velocity in the contralateral coronary artery or change rate-pressure product. Furthermore, both blood flow velocity in the contralateral coronary artery and rate-pressure product were similar at the end of the first and second balloon inflations and were similar to those observed during placebo infusion. Therefore, the vascular effects of phentolamine do not account for the results of our study. Of note, heart rate and blood pressure did not change at the end of balloon inflations; this was probably due to the short duration of myocardial ischemia and the absence, on the average, of severe pain and is consistent with the results of several previous studies.7 8 10 11 12 35

Our findings suggest, therefore, that phentolamine prevented preconditioning during repeated coronary occlusions through the blockade of postsynaptic {alpha}- adrenergic receptors located on the surface of cardiomyocytes. Although the precise mechanism of preconditioning remains elusive, several experimental studies have demonstrated that a variety of G protein-coupled receptors, including {alpha}1-adrenergic, adenosine A1, muscarinic, bradykinin, and endothelin-1 receptors, appear to play an important role in ischemic preconditioning, probably via an upregulation of PKC.13 14 This in turn leads to the translocation of PKC from the cytoplasm to the sarcolemma, where it phosphorylates a substrate protein (possibly the KATP channel), which confers resistance to ischemia.13 14 It has also been suggested that {alpha}1-adrenergic receptor activation may increase 5'-nucleotidase activity, thus increasing adenosine release, which in turn contributes to cause myocardial protection.21 24 Some studies,48 49 however, have shown that the stimulation of {alpha}1-adrenergic receptors alone is insufficient to mimic the cardioprotective effect of ischemic preconditioning in the dog model, raising the possibility that at least in some species, {alpha}1-adrenergic receptors work in parallel with other agonists, such as adenosine and bradykinin, that also stimulate PKC-coupled receptors.50

We previously demonstrated that KATP channels10 and A1 adenosine receptors12 are involved in ischemic preconditioning in humans during brief repeated coronary occlusions. How {alpha}-adrenergic receptors, A1 adenosine receptors, and KATP channels interact in humans in determining preconditioning cannot be deduced from the results of our studies. Whether {alpha}-adrenergic agonist administration during myocardial ischemia in the clinical setting might be useful to improve preconditioning warrants further investigations.

Received February 11, 1997; revision received April 30, 1997; accepted May 13, 1997.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 
1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-1136.[Abstract/Free Full Text]

2. Schott RJ, Rohmann S, Braun ER, Schaper W. Ischemic preconditioning reduces infarct size in swine myocardium. Circ Res. 1990;66:1133-1142.[Abstract/Free Full Text]

3. Cohen MV, Liu GS, Downey JM. Preconditioning causes improved wall motion as well as smaller infarcts after transient coronary occlusion in rabbits. Circulation. 1991;84:341-349.[Abstract/Free Full Text]

4. Li YW, Whittaker P, Kloner RA. The transient nature of the effect of ischemic preconditioning on myocardial infarct size and ventricular arrhythmias. Am Heart J. 1992;123:346-353.[Medline] [Order article via Infotrieve]

5. Ikonomidis JS, Tumiati LC, Weisel RD, Mickle DAG, Li RK. Preconditioning human ventricular cardiomyocytes with brief periods of simulated ischaemia. Cardiovasc Res. 1994;28:1285-1291.[Abstract/Free Full Text]

6. Walker DM, Walker JM, Pugsley WB, Pattison CW, Yellon DM. Preconditioning in isolated superfused human muscle. J Mol Cell Cardiol. 1995;27:1349-1357.[Medline] [Order article via Infotrieve]

7. Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW, Herrmann HC, Laskey WK. Adaptation to ischemia during percutaneous transluminal coronary angioplasty: clinical, hemodynamic, and metabolic features. Circulation. 1990;82:2044-2051.[Abstract/Free Full Text]

8. Tomai F, Crea F, Gaspardone A, Versaci F, Esposito C, Chiariello L, Gioffrè PA. Mechanisms of cardiac pain during coronary angioplasty. J Am Coll Cardiol. 1993;22:1892-1896.[Abstract]

9. Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet. 1993;342:276-277.[Medline] [Order article via Infotrieve]

10. Tomai F, Crea F, Gaspardone A, Versaci F, De Paulis R, Penta de Peppo A, Chiariello L, Gioffrè PA. Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker. Circulation. 1994;90:700-705.[Abstract/Free Full Text]

11. Claeys MJ, Vrints CJ, Bosmans JM, Conraads VM, Snoeck JP. Aminophylline inhibits adaptation to ischemia during angioplasty: role of adenosine in ischaemic preconditioning. Eur Heart J. 1996;17:539-544.[Abstract/Free Full Text]

12. Tomai F, Crea F, Gaspardone A, Versaci F, De Paulis R, Polisca P, Chiariello L, Gioffrè PA. Effects of A1 adenosine receptor blockade by bamiphylline on ischaemic preconditioning during coronary angioplasty. Eur Heart J. 1996;17:846-853.[Abstract/Free Full Text]

13. Lawson CS, Downey JM. Preconditioning: state of the art myocardial protection. Cardiovasc Res. 1993;27:542-550.[Free Full Text]

14. Downey JM, Cohen MV. Mechanisms of preconditioning: correlates and epiphenomena. In: Marber MS, Yellon DM, eds. Ischaemia: Preconditioning and Adaptation. Oxford, UK: UCL Molecular Pathology Series, BIOS Scientific Publishers Limited; 1996:21-34.

15. Banerjee A, Locke-Winter C, Rogers KB, Mitchell MB, Brew EC, Cairns CB, Bensard DD, Harken AH. Preconditioning against myocardial dysfunction after ischemia and reperfusion by an {alpha}1-adrenergic mechanism. Circ Res. 1993;73:656-670.[Abstract/Free Full Text]

16. Bankwala Z, Hale SL, Kloner RA. {alpha}-Adrenoceptor stimulation with exogenous norepinephrine or release of endogenous catecholamines mimics ischemic preconditioning. Circulation. 1994;90:1023-1028.[Abstract/Free Full Text]

17. Tsuchida A, Liu Y, Liu GS, Cohen MV, Downey JM. {alpha}1-Adrenergic agonists precondition rabbit ischemic myocardium independent of adenosine by direct activation of protein kinase C. Circ Res. 1994;75:576-585.[Abstract/Free Full Text]

18. Kaku T, Lakatta E, Filburn C. {alpha}-Adrenergic regulation of phosphoinositide metabolism and protein kinase C in isolated cardiac myocytes. Am J Physiol. 1991;260:C635-C642.[Abstract/Free Full Text]

19. Talosi L, Kranias EG. Effect of {alpha}-adrenergic stimulation on activation of protein kinase C and phosphorylation of proteins in intact rabbit hearts. Circ Res. 1992;70:670-678.[Abstract/Free Full Text]

20. Fedida D, Braun AP, Giles WR. {alpha}1-Adrenoceptors in myocardium: functional aspects and transmembrane signalling mechanisms. Physiol Rev. 1993;73:469-487.[Free Full Text]

21. Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Okazaki Y, Node K, Komamura K, Iwakura K, Itoh T, Inoue M, Kamada T. {alpha}1-Adrenoceptor activation increases ecto-5'-nucleotidase activity and adenosine release in rat cardiomyocytes by activating protein kinase C. Circulation. 1995;91:2226-2234.[Abstract/Free Full Text]

22. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol. 1994;266:H1145-H1152.[Abstract/Free Full Text]

23. Hu K, Nattel S. Mechanisms of ischemic preconditioning in rat hearts: involvement of {alpha}1B-adrenoceptors, pertussin toxin-sensitive G proteins, and protein kinase C. Circulation. 1995;92:2259-2265.[Abstract/Free Full Text]

24. Kitakaze M, Node K, Minamino T, Komamura K, Funaya H, Shinozaki Y, Chujo M, Mori H, Inoue M, Hori M, Kamada T. Role of activation of protein kinase C in the infarct-size limiting effect of ischemic preconditioning through activation of ecto-5'-nucleotidase. Circulation. 1996;93:781-791.[Abstract/Free Full Text]

25. Speechly-Dick ME, Grover GJ, Yellon DM. Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K+ channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Circ Res. 1995;77:1030-1035.[Abstract/Free Full Text]

26. Hoffman BB, Lefkowitz RJ. Adrenergic receptor antagonist. In: Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. New York, NY: McGraw-Hill, Inc; 1990;221-226.

27. Rentrop KP, Cohen M, Blanke H, Phillips R. Changes in collateral filling immediately following controlled coronary artery occlusion by an angioplasty balloon in man. J Am Coll Cardiol. 1985;5:587-592.[Abstract]

28. Cohen M, Rentrop KP. Limitation of myocardial ischemia by collateral circulation during sudden controlled coronary artery occlusion in human subjects: a prospective study. Circulation. 1986;74:469-476.[Abstract/Free Full Text]

29. Tomai F, Crea F, Gaspardone A, Versaci F, De Paulis R, Penta de Peppo A, Bassano C, Chiariello L, Gioffrè PA. Determinants of myocardial ischemia during percutaneous transluminal coronary angioplasty in patients with significant narrowing of a single coronary artery and stable or unstable angina pectoris. Am J Cardiol. 1994;74:1089-1094.[Medline] [Order article via Infotrieve]

30. Orlick AE, Ricci DR, Alderman EL, Stinson EB, Harrison DC. Effects of alpha-adrenergic blockade upon coronary hemodynamics. J Clin Invest. 1978;62:459-467.

31. Heusch GH. {alpha}-Adrenergic mechanisms in myocardial ischemia. Circulation. 1990;81:1-13.[Abstract/Free Full Text]

32. Hodgson JMcB, Cohen MD, Szentpetery S, Thames MD. Effects of regional {alpha}- and ß-blockade on resting and hyperemic coronary blood flow in conscious, unstressed humans. Circulation. 1989;79:797-809.[Abstract/Free Full Text]

33. Kern MJ, Donohue TJ, Bach RG, Aguirre FV, Caracciolo EA, Ofili EO. Quantitating coronary collateral flow velocity in patients during coronary angioplasty using a Doppler guidewire. Am J Cardiol. 1993;71:34D-40D.[Medline] [Order article via Infotrieve]

34. Piek JJ, Koolen JJ, Metting van Rijn AC, Bot H, Hoedemaker G, David GK, Dunning AJ, Spaan JAE, Visser CE. Spectral analysis of flow velocity in the contralateral artery during coronary angioplasty: a new method for assessing collateral flow. J Am Coll Cardiol. 1993;21:1574-1582.[Abstract]

35. Kyriakidis MK, Petropoulakis PN, Tentolouris CA, Marakas SA, Antonopoulos AG, Kourouclis CV, Toutouzas PK. Relation between changes in blood flow of the contralateral coronary artery and the angiographic extent and function of recruitable collateral vessels arising from this artery during balloon coronary occlusion. J Am Coll Cardiol. 1994;23:869-878.[Abstract]

36. Reiber JHC. On-line quantification of coronary angiograms with the DCI system. Medica Mundi. 1989;34:89-98.

37. Tomai F. Ischaemic preconditioning during coronary angioplasty. In: Marber MS, Yellon DM, eds. Ischaemia: Preconditioning and Adaptation. Oxford, UK: UCL Molecular Pathology Series, BIOS Scientific Publishers Limited; 1996:163-185.

38. Huskisson EC. Measurement of pain. Lancet. 1974;2:1127-1131.[Medline] [Order article via Infotrieve]

39. Doucette JW, Corl PD, Payne HM, Flynn AE, Goto M, Nassi M, Segal J. Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation. 1992;85:1899-1911.[Abstract/Free Full Text]

40. Segal J, Kern MJ, Scott NA, King SB III, Doucette JW, Heuser RR, Ofili E, Siegel R. Alterations of phasic coronary artery flow velocity in humans during percutaneous coronary angioplasty. J Am Coll Cardiol. 1992;20:276-286.[Abstract]

41. Friedman PL, Shook TL, Kirschenbaum JM, Selwyn AP, Ganz P. Value of the intracoronary electrocardiogram to monitor myocardial ischemia during percutaneous transluminal coronary angioplasty. Circulation. 1986;74:330-339.[Abstract/Free Full Text]

42. Labovitz AJ, Lewen MK, Kern M, Vandormael M, Deligonal U, Kennedy HL. Evaluation of left ventricular systolic and diastolic dysfunction during transient myocardial ischemia produced by angioplasty. J Am Coll Cardiol. 1987;10:748-755.[Abstract]

43. Shattock MJ, Lawson CS, Hearse DJ, Downey JM. Monophasic action potential and ST-segment changes are indicative of preconditioning only during early ischemia in the pig heart. Circulation. 1995;92(suppl I):I-390. Abstract.

44. Crea F, Pupita G, Galassi AR, El-Tamini H, Kaski JC, Davies G, Maseri A. Role of adenosine in the pathogenesis of anginal pain. Circulation. 1990;81:164-172.[Abstract/Free Full Text]

45. Gaspardone A, Crea F, Tomai F, Versaci F, Iamele M, Gioffrè G, Chiariello L, Gioffrè PA. Muscular and cardiac adenosine-induced pain is mediated by A1 receptors. J Am Coll Cardiol. 1995;25:251-257.[Abstract]

46. Cribier A, Korsatz L, Koning R, Rath P, Gamra H, Stix G, Merchant S, Chan C, Letac B. Improved myocardial ischemic response and enhanced collateral circulation with long repetitive coronary occlusion during angioplasty: a prospective study. J Am Coll Cardiol. 1992;20:578-586.[Abstract]

47. Wikberg JES, Lefkovitz RJ. Adrenergic receptors in the heart: pre and post-synaptic mechanisms. In: Randall WC, ed. Nervous Control of Cardiovasc Function. New York, NY: Oxford University Press; 1984:95-129.

48. Sebbag L, Katsuragawa M, Verbinski S, Jennings RB, Reimer KA. Intracoronary administration of the {alpha}1-receptor agonist, methoxamine, does not reproduce the infarct-limiting effect of ischemic preconditioning in dogs. Cardiovasc Res. 1996;32:830-838.[Medline] [Order article via Infotrieve]

49. Przyklenk K, Sussman MA, Simkhovic BZ, Kloner RA. Does ischemic preconditioning trigger translocation of protein kinase C in the canine model? Circulation. 1995;92:1546-1557.[Abstract/Free Full Text]

50. Goto M, Liu Y, Yang X-M, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res. 1995;77:611-621.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
J. N. Peart and J. P. Headrick
Clinical cardioprotection and the value of conditioning responses
Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1705 - H1720.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
S. D. Solomon, N. S. Anavekar, S. Greaves, J. L. Rouleau, C. Hennekens, M. A. Pfeffer, and HEART Investigators
Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling
J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1511 - 1514.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
T B Lindhardt, N Gadsboll, H Kelbaek, K Saunamaki, J K Madsen, P Clemmensen, B Hesse, and S Haunso
Pharmacological modulation of the ATP sensitive potassium channels during repeated coronary occlusions: no effect on myocardial ischaemia or function
Heart, April 1, 2004; 90(4): 425 - 430.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
M. J L DeJongste, R. A Tio, and R. D Foreman
Chronic therapeutically refractory angina pectoris
Heart, February 1, 2004; 90(2): 225 - 230.
[Full Text] [PDF]


Home page
Br J AnaesthHome page
M. Zaugg, E. Lucchinetti, C. Garcia, T. Pasch, D. R. Spahn, and M. C. Schaub
Anaesthetics and cardiac preconditioning. Part II. Clinical implications
Br. J. Anaesth., October 1, 2003; 91(4): 566 - 576.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
D. M. YELLON and J. M. DOWNEY
Preconditioning the Myocardium: From Cellular Physiology to Clinical Cardiology
Physiol Rev, October 1, 2003; 83(4): 1113 - 1151.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
R J Edwards, S R Redwood, P D Lambiase, E Tomset, R D Rakhit, and M S Marber
Antiarrhythmic and anti-ischaemic effects of angina in patients with and without coronary collaterals
Heart, December 1, 2002; 88(6): 604 - 610.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. A Kloner, M. T Speakman, and K. Przyklenk
Ischemic preconditioning: a plea for rationally targeted clinical trials
Cardiovasc Res, August 15, 2002; 55(3): 526 - 533.
[Full Text] [PDF]


Home page
ChestHome page
Z. S. Kyriakides, S. Psychari, E. K. Iliodromitis, T. M. Kolettis, E. Sbarouni, and D. T. Kremastinos
Hyperlipidemia Prevents the Expected Reduction of Myocardial Ischemia on Repeated Balloon Inflations During Angioplasty*
Chest, April 1, 2002; 121(4): 1211 - 1215.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
S. Salvi
Protecting the Myocardium From Ischemic Injury : A Critical Role for {{alpha}}1-Adrenoreceptors?
Chest, April 1, 2001; 119(4): 1242 - 1249.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
Z. S. Kyriakides, D. Th. Kremastinos, T. M. Kolettis, A. Tasouli, A. Antoniadis, and D. J. Webb
Acute Endothelin-A Receptor Antagonism Prevents Normal Reduction of Myocardial Ischemia on Repeated Balloon Inflations During Angioplasty
Circulation, October 17, 2000; 102(16): 1937 - 1943.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
D. M. Yellon and A. Dana
The Preconditioning Phenomenon : A Tool for the Scientist or a Clinical Reality?
Circ. Res., September 29, 2000; 87(7): 543 - 550.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
W. E. Johnston
Preconditioning the Brain and Heart: Implications for Cardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia, July 1, 2000; 4(2): 70 - 79.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
F. Tomai, F. Crea, and P. A. Gioffre
Preconditioning, collateral recruitment and adenosine
J. Am. Coll. Cardiol., January 1, 2000; 35(1): 259 - 259.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. A. Leesar, M. F. Stoddard, S. Manchikalapudi, and R. Bolli
Bradykinin-induced preconditioning in patients undergoing coronary angioplasty
J. Am. Coll. Cardiol., September 1, 1999; 34(3): 639 - 650.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. Tomai, F. Crea, L. Chiariello, and P. A. Gioffre
Ischemic Preconditioning in Humans : Models, Mediators, and Clinical Relevance
Circulation, August 3, 1999; 100(5): 559 - 563.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
F. Tomai, F. Crea, A. Gaspardone, F. Versaci, A. S. Ghini, C. Ferri, G. Desideri, L. Chiariello, and P. A. Gioffre
Effects of naloxone on myocardial ischemic preconditioning in humans
J. Am. Coll. Cardiol., June 1, 1999; 33(7): 1863 - 1869.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
W. K. Laskey
Beneficial Impact of Preconditioning During PTCA on Creatine Kinase Release
Circulation, April 27, 1999; 99(16): 2085 - 2089.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
M. Billinger, M. Fleisch, F. R. Eberli, A. Garachemani, B. Meier, and C. Seiler
Is the development of myocardial tolerance to repeated ischemia in humans due to preconditioning or to collateral recruitment?
J. Am. Coll. Cardiol., March 15, 1999; 33(4): 1027 - 1035.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
C. Seiler, M. Billinger, R. Bolli, M. M. Leesar, M. M. Ahmed, M. M. Stoddard, and M. J. Broadbent
Adenosine-Induced Preconditioning of Human Myocardium? • Response
Circulation, August 25, 1998; 98(8): 824 - 825.
[Full Text]


Home page
CirculationHome page
A. Dana, J.-i. Imagawa, D. M Yellon, F. Tomai, F. Crea, A. Gaspardone, and P. A. Gioffre
Phentolamine and Preconditioning During Coronary Angioplasty • Response
Circulation, July 28, 1998; 98(4): 378 - 379.
[Full Text]


This Article
Right arrow Abstract Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tomai, F.
Right arrow Articles by Gioffrè, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tomai, F.
Right arrow Articles by Gioffrè, P. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Angioplasty
Hazardous Substances DB
*PHENTOLAMINE